Main Conference: 1 - 3 June, 2027 | Congress Center, Basel, Switzerland
ADCs & Bioconjugate Track
Accelerating Antibody‑Drug Conjugate Innovation from Discovery to Clinical Impact
Why Attend the ADCs & Bioconjugates Track?
ADCs are among the most complex and promising biologic modalities in development today. Success depends on integrating antibody engineering, chemistry, payload design, pharmacology, and clinical strategy.
This track is designed to help you:
Who Should Attend?
What This Track Covers
The co-located ADCs & Bioconjugates Track delivers over 3 full days of content, including keynotes, 30+ speakers and 5 half-day sessions, each featuring 6 expert speakers from leading pharmaceutical companies, biotech innovators, and academic research institutions.
Bispecific ADCs & AOCs for Improved Delivery
Novel Payloads & ADCs with New Mechanism of Action
High DAR Technologies & Predicting ADC Properties (Tox, Th. Window)
Beyond Topo1 Inhibitors & Finding New Validated Targets for ADCs
Phase 2 & 3 Clinical Updates or Deep Data/Informatics for ADCs
This track is specifically designed for professionals who:
- Are developing or optimising ADC or bioconjugate programmes
- Work at the interface of antibody engineering and chemistry
- Need to improve therapeutic index, safety, or clinical translation
- Want to understand why some ADCs succeed while others fail
- Are responsible for strategic R&D or pipeline decisions


















